Back to Search
Start Over
P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
- Source :
- HemaSphere, Vol 6, Pp 839-840 (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 6
- Database :
- Directory of Open Access Journals
- Journal :
- HemaSphere
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f712e85bfd2c4e67907c75060d9796b6
- Document Type :
- article
- Full Text :
- https://doi.org/10.1097/01.HS9.0000846664.78859.dd